Pioneering new therapies for cancer

Latest News

Benefits
Manager, Contract Manufacturing
Abrogation of resistance against bevacizumab (Bev) by mitochondrial inhibition: a phase 0 randomized trial of Bev plus ME344 or placebo in early HER2-negative breast cancer (HERNEBC), ASCO Annual Meeting, June 2018
Initial Results of a Dose Escalation Study of ME-401, a Selective and Structurally Differentiated PI3Kδ Inhibitor in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), ASCO Annual Me